ArticleLiver cancer2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study.
Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06405321 (Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)
Who cites it
11 citing papers in PubMed.
- Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).Liver cancer · 2026Article
- Adjuvant systemic therapy versus active surveillance after resection following conversion therapy for hepatocellular carcinoma: a propensity score matched study.BMC medicine · 2026Article
- Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study.Liver cancer · 2026Article
- Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).Communications medicine · 2026Article
- The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma.Frontiers in immunology · 2026Article
- Hepatocellular Carcinoma in the Eastern World: Screening, Diagnosis, Staging and Treatment.Current pharmaceutical design · 2026Review
- Optimal timing of surgery after conversion therapy for initially unresectable hepatocellular carcinoma: a multicenter study integrating major pathological response and treatment duration.Frontiers in immunology · 2026Article
- When Resectability Emerges After Systemic Therapy in Hepatocellular Carcinoma: A Proposed Response-Guided Consolidation Framework.Journal of hepatocellular carcinoma · 2026Review
- Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma.Liver cancer · 2025Article
- Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).JHEP reports : innovation in hepatology · 2025Article
- Early PIVKA-II Response Associated with Treatment Efficacy and Survival Outcomes for Patients with Advanced Hepatocellular Carcinoma Receiving Immune Checkpoint Inhibitors and Targeted Therapy.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Uncertainty exists regarding whether hepatectomy enhances the prognosis for initially unresectable hepatocellular carcinoma (HCC) that becomes resectable subsequent to conversion therapy. This study conducted a comparative analysis of survival rates between patients who underwent hepatectomy and those who did not, following complete or partial response to conversion therapy. Methods: This retrospective study examined 300 patients with HCC who underwent hepatectomy following conversion therapy, along with 265 nonsurgical control subjects (215 receiving locoregional/systemic therapy and 50 under active surveillance) across 20 Chinese medical centers from 2019 to 2023. The primary outcomes assessed included overall survival (OS), event-free survival (EFS), recurrence-free survival, and the rate of complete pathological response. Results: Hepatectomy was associated with significantly better OS than locoregional or systemic therapy or active surveillance (the 3-year OS rates were 79.9% and 58.5%, respectively, Conclusions: Hepatectomy can provide a significant OS benefit to patients with initially unresectable HCC that responds partially or completely to conversion therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.